Hikma Revises 2026 Outlook, Raises Branded Growth Forecast
Hikma raised its Branded revenue growth forecast to approximately 10% from 6%–8% and expects a nearly 27% core operating margin. Injectables revenue is now expected to be broadly flat, versus previous low-single-digit growth expectations; its margin outlook remains 27%–28%.
Hikma Pharmaceuticals announced that its trading remains in line with expectations, leading to a narrowed full-year 2026 core operating profit outlook. The company raised its Branded revenue growth forecast to approximately 10%, up from its previous guidance of 6% to 8%, and now expects a core operating margin for the segment of nearly 27%, compared to the prior 25% estimate. Conversely, the company adjusted its Injectables revenue outlook to be broadly flat for the year, down from previous expectations of low-single-digit growth.
The Hikma Rx business continues to demonstrate improved profitability, supported by strong demand for sodium oxybate and recent product launches. The company maintains its core operating margin guidance for the Injectables segment at 27% to 28%.